Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 508 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia / Schizoaffective Disorder Clear all
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Schizoaffective Disorder Using Mifepristone

NCT00725270
View directory record Official record
Conditions
Psychotic Disorders, Depressive Disorder, Major, Depressive Disorder
Interventions
Mifepristone, Placebo Oral Tablet
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Not applicable Interventional Results available

The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.

NCT00466323
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Major Depression
Interventions
Family Member Provider Outreach, Enhanced treatment as usual (e-TAU)
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 70 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
West Los Angeles, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 4 Interventional Results available

Prebiotic Treatment in People With Schizophrenia - Pilot Study

NCT03617783
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Prebiotin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Not applicable Interventional Results available

Cognitive Training for Patients With Schizophrenia

NCT01521026
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Other Primary Psychotic Disorders
Interventions
Cognitive Training
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia

NCT04013555
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
N-acetylcysteine (NAC), Placebo, Tryptophan
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

NCT00641745
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lurasidone HCl, Risperidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
41
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 4 Interventional

Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia

NCT00727103
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Alcohol Dependence, Nicotine Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 69 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use: A Pilot Study

NCT05380583
View directory record Official record
Conditions
Psychosis, Substance Use, Substance Use Disorders, Family, Cannabis, Marijuana, Alcohol, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Mental Disorder
Interventions
CRAFT-EP, TAU
Behavioral
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 4 Interventional Results available

Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders

NCT02582905
View directory record Official record
Conditions
Alcohol Use Disorder, Bipolar Disorder, Schizoaffective Disorder Bipolar Type
Interventions
Placebo, Citicoline, Pregnenolone
Drug · Dietary Supplement
Lead sponsor
Sherwood Brown, MD, PhD
Other
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Miami, Florida • Dallas, Texas • Edinburg, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 14, 2026, 10:33 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With Schizophrenia

NCT07615075
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Healthy
Interventions
Placebo, IL-23
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 14, 2026, 10:33 AM EDT
Recruiting Phase 4 Interventional

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

NCT07213466
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
Interventions
Group Therapy Program, semaglutide, Phentermine-Topiramate, naltrexone and bupropion (combination)
Behavioral · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Not applicable Interventional

Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia

NCT00434980
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Family-Directed Cognitive Adaptation Program
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Not applicable Interventional Results available

Clinical Trial of Dipyridamole in Schizophrenia

NCT00349973
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Dipyridamole, Olanzapine
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 3 Interventional Results available

Long-Acting Injectable Risperidone in the Treatment of Schizophrenia

NCT00132314
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia
Interventions
IM risperidone, oral antipsychotic medication
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
19
States / cities
Tuscaloosa, Alabama • Long Beach, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Oct 14, 2026, 10:33 AM EDT
Completed No phase listed Observational

Genetic Study of Schizophrenia

NCT00001486
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
4,914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Not applicable Interventional Results available

Feasibility Electrical Stimulation Study for Visual Hallucinations

NCT04870710
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
transcranial electrical stimulation
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.

NCT00412373
View directory record Official record
Conditions
Schizoaffective Disorder, Psychotic Disorder
Interventions
Placebo, Paliperidone ER
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
15
States / cities
Cerritos, California • Costa Mesa, California • Garden Grove, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine Augmentation of Targeted Cognitive Training in Schizophrenia

NCT04857983
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 14, 2026, 10:33 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

NCT02462473
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 14, 2026, 10:33 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia

NCT03061136
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Clonazepam, Placebo
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 1 Interventional

Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

NCT02901587
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lu AF35700 (10 mg/day), Lu AF35700 (30 mg/day), Quetiapine (Seroquel XR® 800 mg/day)
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
21 Years to 60 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Not applicable Interventional Results available

Cognitive Adaptive Training for Improving Medication Adherence, Symptoms, and Function in People With Schizophrenia

NCT00455663
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive Adaptation Training, Pharm-Cognitive Adaptation Training, Treatment as usual
Behavioral · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 60 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 14, 2026, 10:33 AM EDT
Completed Phase 2 Interventional Results available

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

NCT01393600
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
NBI-98854, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Little Rock, Arkansas • National City, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 14, 2026, 10:33 AM EDT
Recruiting Phase 2 Interventional

Synbiotic Compound to Reduce Symptoms of Schizophrenia

NCT04226898
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Synbiotic Supplement, Inert Compound
Biological
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Batlimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 14, 2026, 10:33 AM EDT